We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




System for Managing Biologic Specimens

By Biotechdaily staff writers
Posted on 02 Jun 2005
A new system for tracking biologic samples is designed to provide accurate, compliant, and efficient management of biospecimens in the laboratory.

The Sapphire BioBanking Solution was developed in conjunction with the original developers of the Spectrum respository management tool. More...
Although many software products already address smaller pieces of sample management, LabVantage (Bridgewater, NJ, USA) has recognized the need to bring together "best of breed” information management, location tracking, logistics, and compliance features to the life sciences industry.

Sapphire BioBanking is designed to address the unique challenges of specimen collection and banking for clinical operations and pharmaceutical discovery, academic and bioscience research centers, medical institutions, and contract research organizations. It provides a browser-based user interface for quick user acceptance and a built-in Evergreen configuration tool to tailor the same solution to the needs of each laboratory within an organization. This flexibility allows Sapphire BioBanking to readily adapt to a variety of data capture, result management, storage, and specimen-handling circumstances.

The biospecimen tracking module is seamlessly integrated with Sapphire's existing laboratory information management solution for life sciences R&D, which can manage experiments and track vital genomic, proteomic, phenotypic, and other result information about samples. Furthermore, it can easily be integrated with third-party public databases, instruments, clinical trial management systems, electronic data capture systems, and existing laboratory information-management systems.

"The introduction of the Sapphire BioBanking solution will allow LabVantage to more fully address the needs of our life sciences customers as large-scale collection of biospecimens becomes more pervasive,” said Jim Aurelio, CEO of LabVantage.




Related Links:
LabVantage

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Repetitive Pipette
VWR® Stepper Pro
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.